ZA200700553B - Galenic applications of self-emulsifying mixtures of lipidic excipients - Google Patents
Galenic applications of self-emulsifying mixtures of lipidic excipients Download PDFInfo
- Publication number
- ZA200700553B ZA200700553B ZA200700553A ZA200700553A ZA200700553B ZA 200700553 B ZA200700553 B ZA 200700553B ZA 200700553 A ZA200700553 A ZA 200700553A ZA 200700553 A ZA200700553 A ZA 200700553A ZA 200700553 B ZA200700553 B ZA 200700553B
- Authority
- ZA
- South Africa
- Prior art keywords
- mixture
- excipients
- proportions
- active principle
- application according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 141
- 239000000546 pharmaceutical excipient Substances 0.000 title claims description 58
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 138
- 239000004094 surface-active agent Substances 0.000 claims description 38
- 150000002632 lipids Chemical class 0.000 claims description 37
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 claims description 36
- 239000004064 cosurfactant Substances 0.000 claims description 29
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 claims description 27
- 239000008389 polyethoxylated castor oil Substances 0.000 claims description 27
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 claims description 26
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 25
- 238000010521 absorption reaction Methods 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims description 18
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 17
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 claims description 16
- 230000007246 mechanism Effects 0.000 claims description 16
- 235000012424 soybean oil Nutrition 0.000 claims description 16
- 239000003549 soybean oil Substances 0.000 claims description 16
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 13
- NPTLAYTZMHJJDP-KTKRTIGZSA-N [3-[3-[3-[3-[3-[3-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)CO NPTLAYTZMHJJDP-KTKRTIGZSA-N 0.000 claims description 12
- 230000002183 duodenal effect Effects 0.000 claims description 11
- 230000005764 inhibitory process Effects 0.000 claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 229960003511 macrogol Drugs 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- 230000002708 enhancing effect Effects 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000012736 aqueous medium Substances 0.000 claims description 7
- 239000004530 micro-emulsion Substances 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 238000004090 dissolution Methods 0.000 claims description 5
- 230000001804 emulsifying effect Effects 0.000 claims description 5
- -1 lauric acid triglycerides Chemical class 0.000 claims description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 235000011837 pasties Nutrition 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 239000012456 homogeneous solution Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 4
- 229940049964 oleate Drugs 0.000 claims description 4
- 238000009210 therapy by ultrasound Methods 0.000 claims description 4
- 229930186217 Glycolipid Natural products 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 229930182558 Sterol Natural products 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 125000005456 glyceride group Chemical group 0.000 claims description 3
- 230000003993 interaction Effects 0.000 claims description 3
- 230000035515 penetration Effects 0.000 claims description 3
- 150000003904 phospholipids Chemical class 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 150000003432 sterols Chemical class 0.000 claims description 3
- 235000003702 sterols Nutrition 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 claims description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 2
- 239000005639 Lauric acid Substances 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 claims description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 claims description 2
- 125000004494 ethyl ester group Chemical group 0.000 claims description 2
- 239000007903 gelatin capsule Substances 0.000 claims description 2
- 229940080812 glyceryl caprate Drugs 0.000 claims description 2
- 229940087068 glyceryl caprylate Drugs 0.000 claims description 2
- 229940074046 glyceryl laurate Drugs 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 229940102223 injectable solution Drugs 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- 229940049918 linoleate Drugs 0.000 claims description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N methyl undecanoic acid Natural products CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 2
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims description 2
- 229960002446 octanoic acid Drugs 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N anhydrous diethylene glycol Natural products OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 2
- 238000009472 formulation Methods 0.000 description 80
- 239000000243 solution Substances 0.000 description 34
- 230000032258 transport Effects 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 23
- 230000035699 permeability Effects 0.000 description 23
- 239000002609 medium Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 12
- 239000007995 HEPES buffer Substances 0.000 description 12
- 239000012981 Hank's balanced salt solution Substances 0.000 description 12
- 230000004907 flux Effects 0.000 description 12
- 230000031891 intestinal absorption Effects 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 230000007154 intracellular accumulation Effects 0.000 description 11
- 239000000594 mannitol Substances 0.000 description 9
- 239000002356 single layer Substances 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 235000010469 Glycine max Nutrition 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 244000068988 Glycine max Species 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 3
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 3
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229960001783 nicardipine Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229960001722 verapamil Drugs 0.000 description 3
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- 230000009056 active transport Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- GWIKTGZMCPFFRW-NRFANRHFSA-N (2s)-3-[4-[4-oxo-4-(1,4,5,6-tetrahydropyrimidin-2-ylamino)butoxy]phenyl]-2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC=1C=CC=CC=1)C(C=C1)=CC=C1OCCCC(=O)NC1=NCCCN1 GWIKTGZMCPFFRW-NRFANRHFSA-N 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 102000019997 adhesion receptor Human genes 0.000 description 1
- 108010013985 adhesion receptor Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- LDVVMCZRFWMZSG-UHFFFAOYSA-N captan Chemical compound C1C=CCC2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C21 LDVVMCZRFWMZSG-UHFFFAOYSA-N 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0408269A FR2873585B1 (fr) | 2004-07-27 | 2004-07-27 | Nouvelles formulations galeniques de principes actifs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200700553B true ZA200700553B (en) | 2008-05-28 |
Family
ID=34951660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200700553A ZA200700553B (en) | 2004-07-27 | 2007-01-19 | Galenic applications of self-emulsifying mixtures of lipidic excipients |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20080193519A1 (pt) |
| EP (1) | EP1771154A1 (pt) |
| JP (1) | JP2008508191A (pt) |
| KR (1) | KR20070046819A (pt) |
| CN (1) | CN101001608A (pt) |
| AU (1) | AU2005273839A1 (pt) |
| BR (1) | BRPI0513622A (pt) |
| CA (1) | CA2579449A1 (pt) |
| FR (1) | FR2873585B1 (pt) |
| IL (1) | IL180714A0 (pt) |
| MA (1) | MA28748B1 (pt) |
| MX (1) | MX2007001141A (pt) |
| NO (1) | NO20070354L (pt) |
| NZ (1) | NZ552715A (pt) |
| RU (1) | RU2381789C2 (pt) |
| TW (1) | TW200616640A (pt) |
| WO (1) | WO2006018501A1 (pt) |
| ZA (1) | ZA200700553B (pt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1867323A1 (en) * | 2006-06-13 | 2007-12-19 | Farmatron Ltd. | Pharmaceutical compositions with biological barriers permeation enhancing properties |
| MX2010001730A (es) * | 2007-08-21 | 2010-03-10 | Basilea Pharmaceutica Ag | Composicion antimicotica. |
| JP5951489B2 (ja) | 2009-10-16 | 2016-07-13 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 組成物 |
| JP2013209294A (ja) * | 2010-07-30 | 2013-10-10 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 液状医薬組成物 |
| BR112014012444B1 (pt) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． | 天然の併用ホルモン補充療法剤及び療法 |
| KR101542364B1 (ko) * | 2014-10-31 | 2015-08-07 | 대화제약 주식회사 | 탁산을 포함하는 경구 투여용 약학 조성물 |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| EP3435977A4 (en) | 2016-04-01 | 2019-10-16 | Therapeuticsmd, Inc. | PHARMACEUTICAL COMPOSITION OF STEROID HORMONE |
| WO2020123551A1 (en) * | 2018-12-10 | 2020-06-18 | Halo Science LLC | Stable formulations of anesthetics and associated dosage forms |
| CZ309587B6 (cs) * | 2021-01-22 | 2023-05-03 | Oncora S.R.O. | Mikroemulzní prekoncentrát s obsahem kladribinu a způsob jeho přípravy |
| CN114246827B (zh) * | 2022-01-04 | 2023-04-11 | 中山大学 | 一种鱼油微乳制剂及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8916901D0 (en) * | 1989-07-24 | 1989-09-06 | Sandoz Ltd | Improvements in or relating to organic compounds |
| FR2710535B1 (fr) * | 1993-09-30 | 1995-11-24 | Gattefosse Ets Sa | Composition à usage pharmaceutique ou cosmétique apte à former une microémulsion. |
| US6054136A (en) * | 1993-09-30 | 2000-04-25 | Gattefosse S.A. | Orally administrable composition capable of providing enhanced bioavailability when ingested |
| EP0933367A1 (en) * | 1997-12-19 | 1999-08-04 | Hoechst Marion Roussel Deutschland GmbH | Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists |
| WO1999037621A1 (en) * | 1998-01-23 | 1999-07-29 | Aventis Pharma Deutschland Gmbh | Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion |
| AU756752B2 (en) * | 1998-04-01 | 2003-01-23 | Skyepharma Canada Inc. | Anticancer compositions |
| CA2302735A1 (en) * | 1998-07-14 | 2000-01-27 | Em Industries, Inc. | Microdisperse drug delivery systems |
| GB0003685D0 (en) * | 2000-02-17 | 2000-04-05 | Univ Cardiff | Sensitisation of cellular material |
| FR2818905A1 (fr) * | 2000-12-28 | 2002-07-05 | Cll Pharma | Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile |
| FR2827770B1 (fr) * | 2001-07-27 | 2005-08-19 | Gattefosse Ets Sa | Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal |
| AU2002357012A1 (en) * | 2001-11-27 | 2003-06-10 | Transform Pharmaceuticals, Inc. | Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof |
| JP4464814B2 (ja) * | 2002-05-14 | 2010-05-19 | アバーント・ファーマシューティカルズ・（インディア）・リミテッド | アントラニル酸誘導体の水和物の製造方法 |
-
2004
- 2004-07-27 FR FR0408269A patent/FR2873585B1/fr not_active Expired - Fee Related
-
2005
- 2005-07-20 AU AU2005273839A patent/AU2005273839A1/en not_active Abandoned
- 2005-07-20 CA CA002579449A patent/CA2579449A1/en not_active Abandoned
- 2005-07-20 NZ NZ552715A patent/NZ552715A/en not_active IP Right Cessation
- 2005-07-20 BR BRPI0513622-9A patent/BRPI0513622A/pt not_active IP Right Cessation
- 2005-07-20 EP EP05790808A patent/EP1771154A1/fr not_active Withdrawn
- 2005-07-20 WO PCT/FR2005/001853 patent/WO2006018501A1/fr active Application Filing
- 2005-07-20 KR KR1020077001445A patent/KR20070046819A/ko not_active Application Discontinuation
- 2005-07-20 JP JP2007521988A patent/JP2008508191A/ja active Pending
- 2005-07-20 US US11/572,402 patent/US20080193519A1/en not_active Abandoned
- 2005-07-20 MX MX2007001141A patent/MX2007001141A/es not_active Application Discontinuation
- 2005-07-20 RU RU2007107199/15A patent/RU2381789C2/ru not_active IP Right Cessation
- 2005-07-20 CN CNA2005800268156A patent/CN101001608A/zh active Pending
- 2005-07-26 TW TW094125195A patent/TW200616640A/zh unknown
-
2007
- 2007-01-15 IL IL180714A patent/IL180714A0/en unknown
- 2007-01-19 NO NO20070354A patent/NO20070354L/no not_active Application Discontinuation
- 2007-01-19 ZA ZA200700553A patent/ZA200700553B/en unknown
- 2007-01-23 MA MA29627A patent/MA28748B1/fr unknown
-
2010
- 2010-08-27 US US12/870,250 patent/US20110104268A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2579449A1 (en) | 2006-02-23 |
| NZ552715A (en) | 2010-12-24 |
| AU2005273839A1 (en) | 2006-02-23 |
| NO20070354L (no) | 2007-04-17 |
| RU2007107199A (ru) | 2008-09-10 |
| WO2006018501A1 (fr) | 2006-02-23 |
| WO2006018501A8 (fr) | 2007-03-01 |
| RU2381789C2 (ru) | 2010-02-20 |
| EP1771154A1 (fr) | 2007-04-11 |
| JP2008508191A (ja) | 2008-03-21 |
| US20110104268A1 (en) | 2011-05-05 |
| FR2873585A1 (fr) | 2006-02-03 |
| MA28748B1 (fr) | 2007-07-02 |
| CN101001608A (zh) | 2007-07-18 |
| KR20070046819A (ko) | 2007-05-03 |
| IL180714A0 (en) | 2007-06-03 |
| US20080193519A1 (en) | 2008-08-14 |
| BRPI0513622A (pt) | 2008-05-13 |
| FR2873585B1 (fr) | 2006-11-17 |
| MX2007001141A (es) | 2007-04-19 |
| TW200616640A (en) | 2006-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200700553B (en) | Galenic applications of self-emulsifying mixtures of lipidic excipients | |
| KR101759750B1 (ko) | 친수성 약물의 자가 미세-유화 경구용 약제 조성물 및 이의 제조 방법 | |
| Jo et al. | Enhanced intestinal lymphatic absorption of saquinavir through supersaturated self-microemulsifying drug delivery systems | |
| Venkatesh et al. | Self-nano emulsifying drug delivery system (SNEDDS) for oral delivery of atorvastatin-formulation and bioavailability studies | |
| Lu et al. | Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice | |
| Patel et al. | Novel drug delivery approach via self-microemulsifying drug delivery system for enhancing oral bioavailability of asenapine maleate: optimization, characterization, cell uptake, and in vivo pharmacokinetic studies | |
| WO2012061480A2 (en) | Compositions and methods for the delivery of therapeutics | |
| KR20130086551A (ko) | 두타스테라이드 함유 자가 유화 약물전달 시스템용 조성물 및 이의 제조 방법 | |
| Khalid et al. | Nano-sized droplets of self-emulsifying system for enhancing oral bioavailability of chemotherapeutic agent VP-16 in rats: A nano lipid carrier for BCS class IV drugs | |
| Chudasama et al. | A novel lipid-based oral drug delivery system of nevirapine | |
| Benival et al. | In situ lipidization as a new approach for the design of a self microemulsifying drug delivery system (SMEDDS) of doxorubicin hydrochloride for oral administration | |
| EP2310009A2 (en) | Parenteral and oral formulations of benzimidazoles | |
| EP2063708A2 (en) | Liquid pharmaceutical formulations for oral administration of a cgrp antagonist | |
| KR20100064370A (ko) | 항균 조성물 | |
| US6770292B2 (en) | Pharmaceutical compositions for oral administration | |
| Sonawale et al. | Solubility enhancement of lipophilic drugs-solid self micro-emulsifying drug delivery system | |
| KR101608178B1 (ko) | 자가 미세유화 약물전달 시스템을 이용한 아토르바스타틴 칼슘의 경구 투여용 약제 조성물 | |
| Carli et al. | Ubidecarenone nanoemulsified composite systems | |
| KR20210102936A (ko) | 안정적인 마취제 제제 및 관련 복용량 형태 | |
| Yahaya et al. | Piroxicam-loaded self-emulsifying drug delivery system | |
| CN112353761B (zh) | 一种双嘧达莫的自纳米乳制剂及其制备方法 | |
| Jin et al. | Development of self-microemulsifying drug delivery system for enhancing the bioavailability of atorvastatin | |
| KR20230133029A (ko) | 톨밥탄을 포함하는 자가 유화 약물 전달 시스템 조성물 및 이의 제조방법 | |
| Cho et al. | Preparation and evaluation of novel fenofibrate-loaded self-microemulsifying drug delivery system (SMEDDS) | |
| CN117771249A (zh) | 拉帕替尼自微乳组合物及其制备方法 |